Future prospects for mitosis-targeted antitumor therapies.

[1]  T. Ikezoe,et al.  Inhibition of Aurora-A Promotes CD8+ T-Cell Infiltration by Mediating IL10 Production in Cancer Cells , 2020, Molecular Cancer Research.

[2]  B. Kennedy,et al.  The quest to slow ageing through drug discovery , 2020, Nature Reviews Drug Discovery.

[3]  J. Jackson,et al.  BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer , 2020, Cell Death & Differentiation.

[4]  D. Rasco,et al.  First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors. , 2020 .

[5]  M. Serrano,et al.  Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[6]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[7]  D. Surdez,et al.  Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with Navitoclax to induce Rhabdomyosarcoma cell death. , 2019, Cancer research.

[8]  Traci M. Blonquist,et al.  Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. , 2019, The Lancet. Haematology.

[9]  M. Erlander,et al.  Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer , 2019, PloS one.

[10]  Michael L. Wang,et al.  Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma , 2019, Blood.

[11]  Shisong Ma,et al.  Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. , 2019, Cancer research.

[12]  J. Moreaux,et al.  The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma , 2019, British Journal of Cancer.

[13]  G. Salles,et al.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. , 2019, Blood.

[14]  W. Placzek,et al.  Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents , 2019, Cells.

[15]  J. Leonard,et al.  Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Liu,et al.  Cellular Senescence-Inducing Small Molecules for Cancer Treatment. , 2019, Current cancer drug targets.

[17]  U. Surana,et al.  Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis , 2019, Front. Cell Dev. Biol..

[18]  K. Venkatakrishnan,et al.  Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial , 2019, JAMA oncology.

[19]  James J. Evans,et al.  Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  K. Khanna,et al.  Mitotic slippage: an old tale with a new twist , 2019, Cell cycle.

[21]  L. Magnaghi-Jaulin,et al.  Aurora A Protein Kinase: To the Centrosome and Beyond , 2019, Biomolecules.

[22]  Ana C. Henriques,et al.  Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. , 2019, Cancer letters.

[23]  R. Schlenk,et al.  A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia , 2018, British journal of haematology.

[24]  M. Hammer,et al.  Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma , 2018, Oncotarget.

[25]  K. Fu,et al.  PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas , 2018, The Journal of clinical investigation.

[26]  P. Clarke,et al.  Timed degradation of Mcl-1 controls mitotic cell death , 2018, Molecular & cellular oncology.

[27]  Hong Chen,et al.  Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis , 2018, Cancer science.

[28]  M. Rubin,et al.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers , 2018, Clinical Cancer Research.

[29]  J. Berlin,et al.  Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer , 2018, Investigational New Drugs.

[30]  Zhenyu Xue,et al.  Identification of JNK1 as a predicting biomarker for ABT‐199 and paclitaxel combination treatment , 2018, Biochemical pharmacology.

[31]  S. Collina,et al.  Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. , 2018, Bioorganic & medicinal chemistry letters.

[32]  S. Groshen,et al.  Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma , 2018, Clinical Cancer Research.

[33]  G. Kops,et al.  Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis , 2018, Open Biology.

[34]  J. Desai,et al.  A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors , 2018, Investigational New Drugs.

[35]  Yuan Gao,et al.  Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. , 2018, Oncology reports.

[36]  Chengyu Liu,et al.  Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma , 2018, Cell Death & Disease.

[37]  S. Lawler,et al.  Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells , 2018, Neuro-oncology.

[38]  S. Liewer,et al.  Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors , 2018, Expert opinion on investigational drugs.

[39]  S. Rottenberg,et al.  New tools for old drugs: Functional genetic screens to optimize current chemotherapy , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  M. Schosserer,et al.  The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy , 2017, Front. Oncol..

[41]  T. Mitchison,et al.  Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug? , 2017, Open Biology.

[42]  L. Zitvogel,et al.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics , 2017, Oncoimmunology.

[43]  A. DeMichele,et al.  Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor , 2017, EBioMedicine.

[44]  S. Janz,et al.  Chromosomal instability and acquired drug resistance in multiple myeloma , 2017, Oncotarget.

[45]  Manish R. Patel,et al.  Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies , 2017, Investigational New Drugs.

[46]  J. Visvader,et al.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.

[47]  S. Loi,et al.  Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). , 2017, Breast.

[48]  Q. Ni,et al.  High Eg5 expression predicts poor prognosis in breast cancer , 2017, Oncotarget.

[49]  E. Rasmussen,et al.  A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemia , 2017, American journal of hematology.

[50]  W. Qi,et al.  Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas , 2017, Molecular Cancer Therapeutics.

[51]  J. Kinoshita,et al.  Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer. , 2017, Oncology reports.

[52]  G. Acton,et al.  A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia , 2017, Pediatric blood & cancer.

[53]  Diego Bonatto,et al.  Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆ , 2017, Pharmacology & therapeutics.

[54]  H. Maiato,et al.  Mechanisms of Chromosome Congression during Mitosis , 2017, Biology.

[55]  A. Eastman,et al.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs , 2017, British journal of clinical pharmacology.

[56]  Kaori Sasai,et al.  Functional Significance of Aurora Kinases–p53 Protein Family Interactions in Cancer , 2016, Front. Oncol..

[57]  F. Peng,et al.  Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy , 2016, Medicinal research reviews.

[58]  B. Leiby,et al.  A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone , 2016, The oncologist.

[59]  E. Schröck,et al.  Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny. , 2016, Carcinogenesis.

[60]  Rachel A. Kudgus,et al.  Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  K. Venkatakrishnan,et al.  Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors , 2016, Cancer.

[62]  Stephen S. Taylor,et al.  Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers , 2016, Open Biology.

[63]  M. Minden,et al.  A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia , 2016, Investigational New Drugs.

[64]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[65]  E. Oki,et al.  Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis , 2016, Oncology.

[66]  E. Kasap,et al.  The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma , 2016, Tumor Biology.

[67]  B. Geoerger,et al.  Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. , 2016, Anticancer research.

[68]  J. Lunceford,et al.  A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors , 2016, Investigational New Drugs.

[69]  J. Moreaux,et al.  Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells , 2015, Oncotarget.

[70]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[71]  M. Okaniwa,et al.  A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity , 2015, PloS one.

[72]  T. Mak,et al.  Targeting Mitosis in Cancer: Emerging Strategies. , 2015, Molecular cell.

[73]  A. Musacchio,et al.  The Aurora B Kinase in Chromosome Bi-Orientation and Spindle Checkpoint Signaling , 2015, Front. Oncol..

[74]  Yuan Cheng,et al.  Targeting the Mitotic Catastrophe Signaling Pathway in Cancer , 2015, Mediators of inflammation.

[75]  J. Radford,et al.  A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma , 2015, British journal of haematology.

[76]  G. Schwartz,et al.  Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression , 2015, Cell cycle.

[77]  P. Workman,et al.  Abstract 5450: Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug-resistance , 2015 .

[78]  Zhiwei Wang,et al.  Targeting Cdc20 as a novel cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.

[79]  K. Venkatakrishnan,et al.  Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose , 2015, Investigational New Drugs.

[80]  M. Werner,et al.  Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. , 2015, Leukemia research.

[81]  D. Colin,et al.  Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins , 2015, Open Biology.

[82]  E. Sausville,et al.  First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors , 2015, Investigational New Drugs.

[83]  Sushama Sivakumar,et al.  Spatiotemporal regulation of the anaphase-promoting complex in mitosis , 2015, Nature Reviews Molecular Cell Biology.

[84]  Zhe Zhang,et al.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. , 2014, Cancer research.

[85]  S. Halford,et al.  A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study , 2014, Clinical Cancer Research.

[86]  A. Gianella-Borradori,et al.  A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors , 2014, Targeted Oncology.

[87]  Timothy B Sackton,et al.  Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C , 2014, Nature.

[88]  A. Nagler,et al.  A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia , 2014, Blood Cancer Journal.

[89]  R. Poon,et al.  p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases , 2014, Oncogene.

[90]  Jerome T. Mettetal,et al.  Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib) , 2014, Molecular Cancer Therapeutics.

[91]  Manuel Serrano,et al.  Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.

[92]  D. Mount,et al.  Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2 , 2014, PloS one.

[93]  A. Letai,et al.  Bcl-xL controls a switch between cell death modes during mitotic arrest , 2014, Cell Death and Disease.

[94]  R. Kurzrock,et al.  Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study , 2014, Investigational New Drugs.

[95]  Bin Zhang,et al.  Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer , 2014, Journal of immunology research.

[96]  S. Akinaga,et al.  A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[97]  A. Maurer,et al.  Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  E. Raymond,et al.  A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors , 2014, Investigational New Drugs.

[99]  R. Burger,et al.  PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Stephen S. Taylor,et al.  Mitosis and apoptosis: how is the balance set? , 2013, Current opinion in cell biology.

[101]  Henk M. W. Verheul,et al.  Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis , 2013, British Journal of Cancer.

[102]  H. Kantarjian,et al.  Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. , 2013, Clinical lymphoma, myeloma & leukemia.

[103]  T. Chambers,et al.  Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death , 2013, Cell Death and Disease.

[104]  T. Baère,et al.  A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma , 2013, Investigational New Drugs.

[105]  J. Naval,et al.  Antimitotic drugs in cancer chemotherapy: promises and pitfalls. , 2013, Biochemical pharmacology.

[106]  G. Martinelli,et al.  A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. , 2013, Leukemia research.

[107]  H. Kantarjian,et al.  Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia , 2013, Cancer.

[108]  A. M. Ishov,et al.  Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy , 2013, Cell cycle.

[109]  H. Vesselle,et al.  Polyploidy road to therapy‐induced cellular senescence and escape , 2013, International journal of cancer.

[110]  Jeffrey Ecsedy,et al.  The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas , 2013, Cancer.

[111]  T. Fojo,et al.  Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response , 2013, Clinical Cancer Research.

[112]  P. Albers,et al.  Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer , 2013, Investigational New Drugs.

[113]  Robert Williams.  Discontinued drugs in 2011: oncology drugs , 2013, Expert opinion on investigational drugs.

[114]  T. Kapoor,et al.  Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore , 2012, Nature Reviews Molecular Cell Biology.

[115]  H. Selby,et al.  Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models , 2012, Clinical Cancer Research.

[116]  S. Barillé-Nion,et al.  Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. , 2012, Anticancer research.

[117]  C. Koh,et al.  Mitosis-targeted anti-cancer therapies: where they stand , 2012, Cell Death and Disease.

[118]  T. Chambers,et al.  Cyclin-dependent Kinase-1 (Cdk1)/Cyclin B1 Dictates Cell Fate after Mitotic Arrest via Phosphoregulation of Antiapoptotic Bcl-2 Proteins* , 2012, The Journal of Biological Chemistry.

[119]  A. Marcus,et al.  A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias , 2012, Cancer.

[120]  M. Minden,et al.  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia , 2012, Investigational New Drugs.

[121]  E. Heath,et al.  First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer , 2012, Cancer Chemotherapy and Pharmacology.

[122]  Timothy J. Mitchison,et al.  The proliferation rate paradox in antimitotic chemotherapy , 2012, Molecular biology of the cell.

[123]  J. Cortés,et al.  Beyond taxanes: the next generation of microtubule-targeting agents , 2011, Breast Cancer Research and Treatment.

[124]  M. M. Mc Gee,et al.  Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis , 2011, Cell cycle.

[125]  Robert Williams.  Discontinued drugs in 2010: oncology drugs , 2011, Expert opinion on investigational drugs.

[126]  Sun Yan,et al.  Prognostic significance of Aurora-A expression in human bladder cancer. , 2011, Acta histochemica.

[127]  C. Rieder,et al.  Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells , 2011, Molecular biology of the cell.

[128]  T. Mitchison,et al.  Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. , 2011, Cancer research.

[129]  H. Lenz,et al.  Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer , 2011, The Pharmacogenomics Journal.

[130]  Suzanne F. Jones,et al.  Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[131]  D. Mahadevan,et al.  Update on aurora kinase targeted therapeutics in oncology , 2011, Expert opinion on drug discovery.

[132]  Arijit Chakravarty,et al.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. , 2011, Cancer research.

[133]  Jason Clark,et al.  Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[134]  T. Mitchison,et al.  Stochastic Competition between Mechanistically Independent Slippage and Death Pathways Determines Cell Fate during Mitotic Arrest , 2010, PloS one.

[135]  I. Cheeseman,et al.  Sensing centromere tension: Aurora B and the regulation of kinetochore function. , 2010, Trends in cell biology.

[136]  D. Oh,et al.  Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. , 2010, Cancer cell.

[137]  Arijit Chakravarty,et al.  Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics , 2010, Molecular Cancer Therapeutics.

[138]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[139]  P. Clarke,et al.  Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest , 2010, The EMBO journal.

[140]  K. Glaser,et al.  Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization , 2010, Proceedings of the National Academy of Sciences.

[141]  Clive S Mason,et al.  Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. , 2010, ACS chemical biology.

[142]  A. Mcdonald,et al.  MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo , 2010, Molecular Cancer Research.

[143]  Y. Shukla,et al.  Role of senescence and mitotic catastrophe in cancer therapy , 2010, Cell Division.

[144]  Robert Williams.  Discontinued drugs in 2008: oncology drugs , 2009, Expert opinion on investigational drugs.

[145]  M. Yen,et al.  Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients , 2009, Virchows Archiv.

[146]  C. Swanton,et al.  Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy , 2009, Cell cycle.

[147]  T. Mitchison,et al.  Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. , 2009, Cancer cell.

[148]  J. Fitzgibbon,et al.  AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. , 2009, Cancer research.

[149]  H. Saya,et al.  K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. , 2009, Cancer research.

[150]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[151]  A. Musacchio,et al.  Molecular basis of drug resistance in aurora kinases. , 2008, Chemistry & biology.

[152]  R. Flavell,et al.  Multisite phosphorylation regulates Bim stability and apoptotic activity. , 2008, Molecular cell.

[153]  M. Justice,et al.  Overexpression of Eg5 causes genomic instability and tumor formation in mice. , 2007, Cancer research.

[154]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[155]  B. Druker,et al.  Applying the discovery of the Philadelphia chromosome. , 2007, The Journal of clinical investigation.

[156]  M. Blagosklonny.  Mitotic Arrest and Cell Fate: Why and How Mitotic Inhibition of Transcription Drives Mutually Exclusive Events , 2007, Cell cycle.

[157]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[158]  A. Sparreboom,et al.  Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. , 2006, Current neuropharmacology.

[159]  P. Chieffi,et al.  Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation , 2006, The Prostate.

[160]  C. Bueso-Ramos,et al.  Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[161]  S. Horwitz,et al.  The Microtubule Stabilizing Agent Discodermolide is a Potent Inducer of Accelerated Cell Senescence , 2005, Cell cycle.

[162]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[163]  S. Haldar,et al.  Identification of a novel Bcl‐xL phosphorylation site regulating the sensitivity of taxol‐ or 2‐methoxyestradiol‐induced apoptosis , 2003, FEBS letters.

[164]  C. Dunton.  Management of treatment-related toxicity in advanced ovarian cancer. , 2002, The oncologist.

[165]  R. Petersen,et al.  Targeting mitosis exit: A brake for cancer cell proliferation. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[166]  I. Vitale,et al.  Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases. , 2017, International review of cell and molecular biology.

[167]  Anna-Maria Olziersky,et al.  Clinical Development of Anti-mitotic Drugs in Cancer. , 2017, Advances in experimental medicine and biology.

[168]  D. Hyman,et al.  A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. , 2017, Gynecologic oncology.

[169]  Geert J P L Kops,et al.  Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling. , 2015, Trends in cell biology.

[170]  J. Y. Lee,et al.  Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells , 2013, Apoptosis.

[171]  Jennifer Hayes Clark,et al.  MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia , 2013, Leukemia.

[172]  S. Cook,et al.  CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. , 2012, Cellular signalling.

[173]  S. Gross,et al.  Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells , 2009, Leukemia.

[174]  P. Chieffi,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):928–935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1518 Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phe , 2004 .